Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

88 results about "Amniotic epithelial cells" patented technology

An amniotic epithelial cell is a form of stem cell extracted from the lining of the inner membrane of the placenta. Amniotic epithelial cells start to develop around 8 days post fertilization. These cells are known to have some of the same markers as embryonic stem cells, more specifically, Oct-4 and nanog. These transcription factors are the basis of the pluripotency of stem cells. Amniotic epithelial cells have the ability to develop into any of the three germ layers: endoderm, mesoderm, and ectoderm. They can develop into several organ tissues specific to these germ layers including heart, brain, and liver. The pluripotency of the human amniotic epithelial cells makes them useful in treating and fighting diseases and disorders of the nervous system as well as other tissues of the human body. Artificial heart valves and working tracheas, as well as muscle, fat, bone, heart, neural and liver cells have all been engineered using amniotic stem cells. Tissues obtained from amniotic cell lines show promise for patients suffering from congenital diseases or malformations of the heart, liver, lungs, kidneys, and cerebral tissue.

Method for simultaneously extracting epithelial cells and mesenchymal stem cells from umbilical cord and placenta amnion tissues

The invention relates to a method for simultaneously extracting epithelial cells and mesenchymal stem cells from umbilical cord and placenta amnion tissues. The method comprises the steps of (1) sampling umbilical cord and placenta amnia and inoculating; (2) performing amplifying and passage on mesenchymal stem cells and amnion epithelial cells in a culture flask; (3) identifying the mesenchymal stem cells and the amnion epithelial cells: 1) when culture cells is transferred to the third generation, identifying the purity of culture cells after trypsinization; 2) verifying the cell purity to be 90 percent or more, namely the standard is met, and a mixture of the epithelial cells and the mesenchymal stem cells is obtained. The method is low in cost, simple and rapid, umbilical cord and placenta amnia are cut into tiny pieces by using a tissue cutting machine, which is conducive to swimming out of the tissues after the cells are directly inoculated in the culture flask; the cost is greatly lowered due to the fact that no proteinase reagent is used, and the preparation time is reduced, so that large-scale cell preparation in short time is realized; the method uses cell culture mediums being added with growth factors and other nutrients, and serum is saved.
Owner:斯坦姆(天津)生物技术研究有限公司

Separation, purification and identification methods of human amnion mesenchymal stem cells

The invention discloses separation, purification and identification methods of human amnion mesenchymal stem cells. The separation method of hAMSCs (human amnion mesenchymal stem cells) comprises the following steps: fragmentating human amnion; and carrying out two-step rotating digestion with trypsin of EDTA (ethylene diamine tetra-acetic acid) and collagenase of DNaseI, filtering with a steel mesh and collecting cell filtrate namely separated original hAMSCs. The purification method of hAMSCs comprises the following steps: incubating original hAMSCs with an LG (low glucose)-DMEM (dulbecco modified eagle medium) culture medium in a CO2 incubator; removing amnion epithelial cells which do not perform complete adherence growth under an inverted microscope; replacing a new culture medium on the third day; digesting with a trypsin-EDTA solution after cell converge degree reaches 80-90%; and collecting cells so as to obtain high-purity hAMSCs. The identification method of hAMSCs comprises the following steps: identifying hAMSCs and the amnion epithelial cells by adopting immunocytochemical staining vimentin and CK19; and detecting expressions of CD29, CD44, CD166, CD34 and CD45 by adopting a flow cytometry. The separation and purification methods disclosed by the invention have the advantages of high yield, high activity and high purity of hAMSCs; and the identification method is simple, convenient and precise.
Owner:AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE

Preparation method of tissue engineering skin containing appendant organs

The invention relates to a preparation method of tissue engineering skin containing appendant organs. In the invention, the preparation method comprises the following steps of: inoculating amniotic mesenchyme stem cells, amniotic mesenchyme stem cells induced to the directions of hair papillae, amniotic epithelial cells and amniotic epithelial cells induced to the directions of the epithelia of the sweat gland into a gel solution, then inoculating the amniotic epithelial cells and the amniotic epithelial cells induced by keratinocyte in a warp direction on the surface of a structure of the hair follicle and the sweat gland after culturing by a dermal layer by induced culture forming the structure of the hair follicle and the sweat gland, and obtaining the tissue engineering skin with the structure of the hair follicle and the sweat gland after culturing. The skin has elasticity, toughness, vigorous cellular metabolism, strong multiplication capacity, sufficient secretion of extracellular matrices, tight linkage of the cuticular layer, the inophragma and the cells of the dermal layer and little possibility of falling off, enhances the success rate of transplantation, can promote the healing of a wound surface, enhances the effects of restoration and replacement and has the function of regulating the immunological rejection of a receptor; by the contained structure of the hair follicle and the sweat gland, the function of the skin is more complete; the adopted amniotic tissues are postpartum wastes and have extensive source, strong cell multiplication capability and multiplepassage frequency; and the invention is beneficial to the mass production of seed cells and lowers the industrialization cost.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY +1

Amnion innate stem cell carried frozen active amnion particle and conditioned medium and application thereof

The invention relates to the technical field of tissue engineering and medical wound repairing, in particular to an amnion innate stem cell carried frozen active amnion particle and a conditioned medium and application thereof. Discarded fresh amnions are prepared into particles and then frozen into liquid nitrogen by means of serum-free stem cell freezing liquid; thus, complete matrix components of amnion are maintained while amnion epithelial cell activity is maintained for a long time, and further, disease transmission is avoided effectively. The conditioned medium which is prepared and collected by means of the frozen active amnion particles can promote chemotaxis and migration of human epidermal cells, fibroblast and endothelial cells effectively. In terms of zoografting, wound healing can be improved by multiple ways of regulating inflammatory reaction, promoting vascularization, quickening epithelization and the like through the active amnion particles; further, the amnion matrix can be directly used as a dermis equivalent to induce dermal regeneration so as to improve wound healing quality remarkably. The amnion innate stem cell carried frozen active amnion particle and the conditioned medium thereof can provide simple but effective ways for wound repairing.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Bletilla striata polysaccharide hydrogel, culture medium and application thereof as well as method of inducing differentiation of umbilical cord mesenchymal stem cells to corneal epithelial cells

The invention relates to the field of cell culture, in particular relates to letilla striata polysaccharide hydrogel, a culture medium and application thereof as well as a method of inducing differentiation of umbilical cord mesenchymal stem cells (hUC-MSCs) to corneal epithelial cells. The method comprises the steps of sulfating letilla striata polysaccharide and then crosslinking with Epsilon-polylysine carrying polyfunctional groups to prepare the polysaccharide hydrogel. The letilla striata polysaccharide hydrogel is of a semi-transparent membrane, has good porosities, and is suitable for the growth and the differentiation of cells. The experiment shows that by taking the letilla striata polysaccharide hydrogel provided by the invention as a scaffold, after the hUC-MSCs and amniotic epithelial cells are subjected to co-culture for 7 days, the differentiation rate of the hUC-MSCs can be up to 31.96%. The differentiation rate (p is less than 0.01) is obviously superior to that of a contrasting example which does not adopt the hydrogel scaffold. In addition, the hydrogel provided by the invention can promote the cells to grow vigorously, and shorten the induction time.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD

Method for manufacturing and storing corneal injury scar-free repairing device

The invention relates to a method for manufacturing and storing a corneal injury scar-free repairing device. Specially-prepared amnion elements are settled or bonded in or on the surfaces of various biological or synthetic attaching devices such as the invisible contact lens through the novel carrier controlled release technology and the biological tissue engineering technology so as to form the corneal or conjunctiva injury scar-free repairing device. At the early stage of the corneal or conjunctiva injury, the affected corneal tissue or the affected conjunctiva tissue is covered with the amnion elements of the corneal or conjunctiva injury scar-free repairing device, the amnion elements, such as the necessary cell growth factors, the tissue repair factors and protease inhibitors, of the corneal or conjunctiva injury scar-free repairing device are diffused to the affected corneal tissue or the affected conjunctiva tissue due to the special superfine structure of an amnion basilar membrane and the stem cell characteristic of amniotic epithelial cells, and therefore growth of epithelial cells of the corneal or the conjunctiva is promoted, the affected corneal tissue or the affected conjunctiva tissue is stimulated, regulated and controlled to heal orderly, and less scars are formed on the affected corneal tissue or the affected conjunctiva tissue.
Owner:广州睿辰生物科技有限公司

Amnion cell separation and collection purification set

An amnion cell separation and collection purification set relates to an amnion cell separation set. The amnion cell separation and collection purification set is used for solving the problems that during amnion cell separation, an amnion is often accumulated in a digestion container, so that a lot of cells are remained among amnion tissues, the amnion cells cannot be efficiently collected, and the obtained cell line is unpurified. The set comprises an amnion cell fixing rotary frame, an amnion tissue digester, an amnion cell separator, a disposable screwed filter, a disposable screwed injector and a disposable screwed centrifuge tube; a threaded circular rod is arranged on the top of a hollow object placing groove of the amnion cell fixing rotary frame; the threaded circular rod is externally connected with a T-shaped handle; a thin plate is arranged in the object placing groove; the amnion tissue digester is of a hollow cube structure; a top cover is arranged on the top of the amnion tissue digester; a liquid inlet screwed opening is formed in one side of the upper part of the amnion tissue digester; a liquid discharge screwed opening is formed in the bottom of the amnion tissue digester; the amnion cell separator is of a hollow cylinder structure; a top cover is arranged on the top of the amnion cell separator; a liquid inlet screwed opening is formed in the side face of the upper part of the amnion cell separator; a liquid discharging screwed opening is formed in the bottom of the amnion cell separator. The amnion cell separation and collection purification set is used for separating and collecting amniotic epithelial cells.
Owner:天晴干细胞股份有限公司

Method for inducing and differentiating into dopaminergic neuron from human amniotic sepithelial cell and application for separating obtained dopaminergic neuron

The invention relates to a method for inducing and differentiating into dopaminergic neurons from human amniotic sepithelial cells, comprising the following steps of: taking a fresh human placenta; stripping a human amnion, repeatedly washing by using normal saline to remove blood clots, then soaking by using asepsis D-hank's liquor, and then rinsing by using the normal saline; placing the human amnion into 0.25 percent of a trypsin solution, and digesting at the temperature of 36.5-37.5 DEG C; stopping the digestion of the human amnion in the trypsin solution by using DMEM / F12 (Dulbecco's Modified Eagle Medium / F12) containing 10 percent of fetal calf serums, and then filtering the solution by using a cell sieve, wherein collected cells are the human amniotic sepithelial cells; separating the obtained human amniotic sepithelial cells, and carrying out in-vitro subculture on the separated human amniotic sepithelial cells by using 10 percent of culture mediums without the fetal calf serums; selecting 3 or 4 or 5 or 6 generation human amniotic sepithelial cells with good growth state, and then continuously culturing by using a neural stem cell differential medium; and harvesting dopaminergic neuron like cells.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Corneal injury scar-free repairing device and application thereof

The invention relates to a corneal injury scar-free repairing device and application thereof. Specially-prepared amnion elements are settled or bonded in or on the surfaces of various biological or synthetic attaching devices such as the invisible contact lens through the novel carrier controlled release technology and the biological tissue engineering technology so as to form the corneal or conjunctiva injury scar-free repairing device. At the early stage of the corneal or conjunctiva injury, the affected corneal tissue or the affected conjunctiva tissue is covered with the amnion elements of the corneal or conjunctiva injury scar-free repairing device, the amnion elements, such as the necessary cell growth factors, the tissue repair factors and protease inhibitors, of the corneal or conjunctiva injury scar-free repairing device are diffused to the affected corneal tissue or the affected conjunctiva tissue due to the special superfine structure of an amnion basilar membrane and the stem cell characteristic of amniotic epithelial cells, and therefore growth of epithelial cells of the corneal or the conjunctiva is promoted, the affected corneal tissue or the affected conjunctiva tissue is stimulated, regulated and controlled to heal orderly, and less scars are formed on the affected corneal tissue or the affected conjunctiva tissue.
Owner:周辉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products